Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 13, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| January 13, 2017 | Ordinary Shares (25p each) | £15.7648 | 255 shares |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions resulting from dividend reinvestment plans (DRIP) within Individual Savings Accounts (ISAs).
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares following the reinvestment of dividends paid on January 12, 2017.
- Participants: Transactions involved Sir Andrew Witty (CEO), Mr. D.S. Redfern (Chief Strategy Officer), Mrs. V.A. Whyte (Company Secretary), and two PCAs related to the CEO.
- Volume Breakdown:
- Sir Andrew Witty: 107 shares
- Mr. D.S. Redfern: 21 shares
- Mrs. V.A. Whyte: 18 shares
- Lady C. Witty (PCA): 49 shares
- Mr. J.P. Witty (PCA): 60 shares
- Market Data: All transactions occurred on the London Stock Exchange (XLON) at a uniform price of £15.7648.